[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE355853T1 - Heterologer schutz, induziert durch immunisierung mit der invaplex-vakzine - Google Patents

Heterologer schutz, induziert durch immunisierung mit der invaplex-vakzine

Info

Publication number
ATE355853T1
ATE355853T1 AT02741716T AT02741716T ATE355853T1 AT E355853 T1 ATE355853 T1 AT E355853T1 AT 02741716 T AT02741716 T AT 02741716T AT 02741716 T AT02741716 T AT 02741716T AT E355853 T1 ATE355853 T1 AT E355853T1
Authority
AT
Austria
Prior art keywords
heterologue
immunization
protection induced
invaplex
invaplex vaccine
Prior art date
Application number
AT02741716T
Other languages
English (en)
Inventor
Edwin V Oaks
Kevin R Turbyfill
Original Assignee
Us Army
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Army filed Critical Us Army
Application granted granted Critical
Publication of ATE355853T1 publication Critical patent/ATE355853T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0283—Shigella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT02741716T 2001-05-18 2002-05-17 Heterologer schutz, induziert durch immunisierung mit der invaplex-vakzine ATE355853T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29215401P 2001-05-18 2001-05-18
US29249301P 2001-05-21 2001-05-21

Publications (1)

Publication Number Publication Date
ATE355853T1 true ATE355853T1 (de) 2007-03-15

Family

ID=26967184

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02741716T ATE355853T1 (de) 2001-05-18 2002-05-17 Heterologer schutz, induziert durch immunisierung mit der invaplex-vakzine

Country Status (9)

Country Link
US (1) US7258863B2 (de)
EP (1) EP1395283B1 (de)
JP (2) JP4510382B2 (de)
AT (1) ATE355853T1 (de)
AU (1) AU2002314793B2 (de)
CA (1) CA2447274C (de)
DE (1) DE60218662T2 (de)
DK (1) DK1395283T3 (de)
WO (1) WO2002094190A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1701737B1 (de) * 2003-11-25 2010-01-13 THE GOVERNMENT OF THE UNITED STATES, as represented by THE SECRETARY OF THE ARMY Verwendung von shigella invaplex für den transport von funktionalen proteinen und transkriptionsaktiven nukleinsäuren durch säugetier-zellmembranen in vitro und in vivo
US7481997B1 (en) 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
CA2563214A1 (en) * 2006-10-12 2008-04-12 Institut Pasteur Shigella ipad protein and its use as a potential vaccine against shigella infection
AU2007349883B2 (en) * 2007-03-27 2013-06-27 The United States Of America As Represented By The Secretary Of The Army, Walter Reed Army Institute Of Research Artificial invaplex
WO2009029795A1 (en) * 2007-08-31 2009-03-05 Amgen Inc. Solid-state protein formulation
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
WO2012055951A2 (en) * 2010-10-27 2012-05-03 Glaxosmithkline Biologicals S.A. Immunogenic composition
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
DE69919754T2 (de) * 1998-09-30 2005-09-01 Walter Reed Army Institute Of Research Verwendung von aufgereinigtem invaplex als impfstoff für gram-negativebakterien

Also Published As

Publication number Publication date
US7258863B2 (en) 2007-08-21
DE60218662T2 (de) 2007-11-08
CA2447274A1 (en) 2002-11-28
JP5149242B2 (ja) 2013-02-20
EP1395283A2 (de) 2004-03-10
DK1395283T3 (da) 2007-07-09
DE60218662D1 (de) 2007-04-19
AU2002314793B2 (en) 2007-08-02
WO2002094190A3 (en) 2003-12-11
EP1395283B1 (de) 2007-03-07
WO2002094190A2 (en) 2002-11-28
EP1395283A4 (de) 2005-06-08
JP2004534762A (ja) 2004-11-18
JP4510382B2 (ja) 2010-07-21
JP2009197031A (ja) 2009-09-03
CA2447274C (en) 2013-11-12
US20020197276A1 (en) 2002-12-26

Similar Documents

Publication Publication Date Title
DE60218662D1 (de) Heterologer schutz, induziert durch immunisierung mit der invaplex-vakzine
ATE489968T1 (de) Proteosom-liposaccharid-vakzine-adjuvans
EP1594536A4 (de) Adjuvante influenza-vakzine
DK1113816T3 (da) Influenzavirus-vaccinesammensætning
AU2003244855A1 (en) Method to enhance an immune response of nucleic acid vaccination
ATE542829T1 (de) Impfstoff
DE60045668D1 (de) Influenzavirus-Impfstoffzusammensetzung
DK1147117T3 (da) Immunologiske adjuvansforbindelser
WO2003011223A3 (en) Immunomodulatory compounds and methods of use thereof
DE69919754D1 (de) Verwendung von aufgereinigtem invaplex als impfstoff für gram-negativebakterien
MA32388B1 (fr) Immunomodulation par des inhibiteurs d'iap
DE69322092D1 (de) Neue bakterielle impfstoffe unter verwendung von impfstämmen von pathogenen bakterien
ATE392216T1 (de) Mycobakterieller impfstoff
ATE529123T1 (de) Synthetische glykolipopeptide als impfstoffe
AU1974992A (en) Pseudomonas exoenzyme s peptide composition and method
DE60011560D1 (de) Salmonella Impfstoff, der keinen Antikörper gegen Flagellin oder gegen Flagella induziert
ATE477274T1 (de) Gegen clostridium difficile gerichtete antikörper
DE60136360D1 (de) Antigen aus streptococcus pyogenes
RS52188B (en) A PSYCHI VACCINE FOR THE PROTECTION OF ERLIHIOSIS
WO2007016715A3 (en) Immune response inducing preparations
WO2005123112A3 (en) Method of enhancing the immune response to a vaccine
ATE431745T1 (de) Ltb4 als adjuvans für impfstoffe
ATE495757T1 (de) Attenuierte bakterielle lebendvakzine
TW200708737A (en) Immunomodulatory compositions
ATE424844T1 (de) Kombinationsvakzine für geflügel

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties